Kailera Therapeutics (KLRA) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 31 130 sessions, April 17, 2026 to October 21, 2026
- Largest daily move
- +16.1% close of October 9, 2026
- 1-month change
- +7.8% closing prices, September 21, 2026 to October 21, 2026
Company Description
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company developing product candidates for obesity care. The company is focused on a pipeline intended to provide treatment options for people living with obesity, with development work centered on GLP-1 based mechanisms of action and multiple routes of administration. Its common stock trades on the Nasdaq Global Select Market under the symbol KLRA.
The company describes an obesity-first development strategy built around four clinical-stage product candidates. Its pipeline focus places Kailera in the biotechnology segment of metabolic and obesity therapeutics, where company value is tied to the advancement, regulatory development, financing, and potential commercialization of investigational medicines rather than to an established commercial product portfolio.
Kailera operates as a public operating company headquartered in Waltham, Massachusetts. The company completed its initial public offering in April 2026, selling common stock and listing on Nasdaq. Public-company records identify Kailera as an emerging growth company and show a Delaware corporate structure with common stock registered under Section 12(b) of the Exchange Act.
As a newly public clinical-stage biotechnology issuer, Kailera's corporate profile is defined by its obesity-focused research and development activities, equity-financed capital structure, public-market listing, and governance framework for a development-stage life sciences company.
Stock Performance
Kailera Therapeutics (KLRA) closed at $12.92 on October 21, 2026. Over the past month, the price has gained 7.8%.
KLRA Metrics & Rankings
Price returns through October 21, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Kailera Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, earnings. View all KLRA news →
SEC Filings
Kailera Therapeutics has filed 10 recent SEC filings, including 3 Form 4, 3 Form SCHEDULE 13G, 2 Form 3, 1 Form 10-Q. The most recent filing was submitted on September 9, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KLRA SEC filings →
Financial Highlights
Upcoming Events
Global Phase 2 readout
Initiate Phase 3 trials
Ribupatide Phase 3 start
KAI-4729 Phase1 data
Oral ribupatide Phase 3
High-dose Phase 2b data
KaiNETIC Phase 3 data
Topline data release
Kailera Therapeutics has 8 upcoming scheduled events. The next event, "Global Phase 2 readout", is scheduled for January 1, 2027 (in 71 days). Investors can track these dates to stay informed about potential catalysts that may affect the KLRA stock price.
Short Interest History
Short interest in Kailera Therapeutics (KLRA) currently stands at 8.7 million shares, up 45.6% from the previous reporting period, representing 9.8% of the float. Since April 2026, short interest has increased by 344.3%.
Days to Cover History
Days to cover for Kailera Therapeutics (KLRA) currently stands at 5.6 days, down 26.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since April 2026, the figure has increased by 388.7%. Across the settlements charted above, it has ranged from 1.1 to 20.1 days.
KLRA Company Profile & Sector Positioning
Kailera Therapeutics (KLRA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.